Besides, it can be observed that both PPARγ antagonist treatment and PPARγ knockdown did not cancel the anti-cancer effect of HSYA totally, suggesting the involvement of other pathways in the HSYA-mediated CRC inhibition, which need to be clarified in the future research. The gene discussed is PPARG; the disease is cancer.